
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AgomAb Therapeutics NV

(Name of Issuer)

Common Shares, no nominal value per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-
-

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Redmile Group, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially

5

Sole Voting Power

0.00

Owned by Each Reporting Person With: 6 Shared Voting Power
2,735,926.00
Sole Dispositive Power
7
0.00
Shared Dispositive Power
8
2,735,926.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,735,926.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)
5.6 %
12 Type of Reporting Person (See Instructions)
IA, OO

Comment for Type of Reporting Person: The information in Item 4 relating to the Issuer's common shares, no nominal value per share ("Common Shares"), that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on April 23, 2026 (the "Form 20-F").

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons
Jeremy C. Green
Check the appropriate box if a member of a Group (see instructions)
2 (a)
 (b)
3 Sec Use Only
4 Citizenship or Place of Organization
UNITED KINGDOM
Sole Voting Power
5
0.00
Number of Shares Beneficially Owned by Each Reporting Person With: 6 Shared Voting Power
2,735,926.00
Sole Dispositive Power
7
0.00
Shared Dispositive Power
8
2,735,926.00
9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,735,926.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11

5.6 %

Type of Reporting Person (See Instructions)

12

HC, IN

Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Redmile Biopharma Investments III, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

2,735,926.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

2,735,926.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,735,926.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

5.6 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Redmile Biopharma Investments III, L.P. ("RBI III") is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F.

SCCHEDULE 13G

Item 1.

Name of issuer:

(a)

AgomAb Therapeutics NV

Address of issuer's principal executive offices:

(b)

Posthoflei 1/6, 2600 Antwerpen, Belgium

Item 2.

Name of person filing:

(a)

Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P.

Address or principal business office or, if none, residence:

(b)

Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
Citizenship:

(c)

Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware

Title of class of securities:

(d)

Common Shares, no nominal value per share

(e)

CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a)

There is no CUSIP number assigned to the Common Shares. CUSIP number 00860C102 has been assigned to the American Depositary Shares (ADSs) of the Issuer. Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1)

Percent of class:

(b)

Redmile Group, LLC - 5.6% (2) Jeremy C. Green - 5.6% (2) Redmile Biopharma Investments III, L.P. - 5.6% (2) %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0

(ii) Shared power to vote or to direct the vote:

Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1)

(iii) Sole power to dispose or to direct the disposition of:

Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0

(iv) Shared power to dispose or to direct the disposition of:

Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1) (1) As of March 31, 2026, each of the reporting person's beneficial ownership of Common Shares is comprised of 2,579,676 Common Shares and 156,250 American Depositary Shares ("ADS"), each representing one Common Share. The Common Shares and ADS are directly held by RBI III, a private investment vehicle for which Redmile is the investment manager. Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all Common Shares held by RBI III. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See the response to Item 4.

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature: /s/ Jeremy C. Green

Name/Title: Managing Member

Date: 05/15/2026

Jeremy C. Green

Signature: /s/ Jeremy C. Green

Name/Title: Jeremy C. Green

Date: 05/15/2026

Redmile Biopharma Investments III, L.P.

Signature: /s/ Jeremy C. Green

Managing Member of Redmile Biopharma
Name/Title: Investments III (GP), LLC, general partner of
Redmile Biopharma Investments III, L.P.

Date: 05/15/2026